| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 105 | 2024 | 4808 | 8.050 |
Why?
|
| Bipolar Disorder | 114 | 2024 | 5138 | 7.300 |
Why?
|
| Antidepressive Agents | 63 | 2024 | 2897 | 5.550 |
Why?
|
| Electronic Health Records | 44 | 2024 | 4873 | 4.000 |
Why?
|
| Natural Language Processing | 20 | 2022 | 1203 | 2.340 |
Why?
|
| Irritable Mood | 6 | 2025 | 196 | 2.250 |
Why?
|
| Fluoxetine | 13 | 2015 | 729 | 2.070 |
Why?
|
| Suicide | 13 | 2023 | 1604 | 2.010 |
Why?
|
| Depression | 32 | 2024 | 8237 | 1.830 |
Why?
|
| Pharmacogenetics | 19 | 2020 | 682 | 1.820 |
Why?
|
| Citalopram | 15 | 2022 | 402 | 1.800 |
Why?
|
| Mental Disorders | 23 | 2024 | 6853 | 1.770 |
Why?
|
| Induced Pluripotent Stem Cells | 15 | 2023 | 1883 | 1.760 |
Why?
|
| Schizophrenia | 28 | 2024 | 6972 | 1.730 |
Why?
|
| Suicide, Attempted | 18 | 2022 | 1409 | 1.730 |
Why?
|
| Antidepressive Agents, Second-Generation | 8 | 2014 | 490 | 1.650 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 20 | 2020 | 1989 | 1.590 |
Why?
|
| Depressive Disorder | 21 | 2018 | 3714 | 1.540 |
Why?
|
| Antimanic Agents | 13 | 2020 | 523 | 1.480 |
Why?
|
| Delirium | 7 | 2021 | 1707 | 1.430 |
Why?
|
| Patient Readmission | 7 | 2021 | 3286 | 1.400 |
Why?
|
| Genome-Wide Association Study | 42 | 2024 | 12807 | 1.390 |
Why?
|
| Psychiatry | 10 | 2020 | 1714 | 1.370 |
Why?
|
| Anxiety Disorders | 15 | 2024 | 2737 | 1.350 |
Why?
|
| Authorship | 4 | 2022 | 288 | 1.350 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 14 | 2021 | 3719 | 1.350 |
Why?
|
| Humans | 375 | 2025 | 765968 | 1.340 |
Why?
|
| Calcium Channels, L-Type | 8 | 2017 | 242 | 1.330 |
Why?
|
| Female | 247 | 2025 | 396112 | 1.320 |
Why?
|
| Cytochrome P-450 Enzyme System | 6 | 2017 | 423 | 1.290 |
Why?
|
| Adult | 182 | 2025 | 223044 | 1.270 |
Why?
|
| Mood Disorders | 6 | 2021 | 1128 | 1.270 |
Why?
|
| Male | 221 | 2025 | 363698 | 1.270 |
Why?
|
| Psychiatric Status Rating Scales | 37 | 2022 | 6014 | 1.260 |
Why?
|
| Medication Adherence | 8 | 2020 | 2192 | 1.250 |
Why?
|
| Thiophenes | 6 | 2012 | 569 | 1.230 |
Why?
|
| Polymorphism, Single Nucleotide | 51 | 2021 | 16047 | 1.180 |
Why?
|
| Lithium | 7 | 2024 | 597 | 1.150 |
Why?
|
| Bibliometrics | 3 | 2021 | 357 | 1.150 |
Why?
|
| Antipsychotic Agents | 17 | 2019 | 3076 | 1.130 |
Why?
|
| Microglia | 7 | 2024 | 1372 | 1.080 |
Why?
|
| Narration | 3 | 2021 | 223 | 1.060 |
Why?
|
| Personality Disorders | 4 | 2020 | 727 | 1.050 |
Why?
|
| Psychotropic Drugs | 9 | 2019 | 879 | 1.020 |
Why?
|
| Genetic Predisposition to Disease | 36 | 2021 | 18071 | 1.010 |
Why?
|
| Cohort Studies | 46 | 2024 | 41649 | 0.980 |
Why?
|
| Middle Aged | 122 | 2025 | 223009 | 0.970 |
Why?
|
| Central Nervous System Stimulants | 5 | 2024 | 1167 | 0.940 |
Why?
|
| Drug Discovery | 3 | 2019 | 1064 | 0.940 |
Why?
|
| Self Report | 8 | 2025 | 3770 | 0.930 |
Why?
|
| Genetic Loci | 7 | 2019 | 2631 | 0.910 |
Why?
|
| Hospitals, General | 3 | 2021 | 802 | 0.910 |
Why?
|
| Genotype | 37 | 2020 | 13024 | 0.890 |
Why?
|
| Lithium Carbonate | 4 | 2014 | 179 | 0.890 |
Why?
|
| Psychopathology | 5 | 2024 | 435 | 0.880 |
Why?
|
| Hospitalization | 17 | 2024 | 10808 | 0.880 |
Why?
|
| Databases, Genetic | 4 | 2020 | 1751 | 0.870 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2019 | 499 | 0.850 |
Why?
|
| Benzodiazepines | 9 | 2012 | 1136 | 0.840 |
Why?
|
| Psychotic Disorders | 15 | 2024 | 3270 | 0.840 |
Why?
|
| Neural Stem Cells | 6 | 2023 | 898 | 0.840 |
Why?
|
| Pandemics | 16 | 2024 | 8703 | 0.840 |
Why?
|
| Suicidal Ideation | 5 | 2023 | 1461 | 0.830 |
Why?
|
| Biomarkers, Pharmacological | 4 | 2015 | 162 | 0.820 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2016 | 251 | 0.810 |
Why?
|
| Publishing | 2 | 2021 | 835 | 0.810 |
Why?
|
| Lithium Compounds | 8 | 2020 | 226 | 0.800 |
Why?
|
| Trust | 2 | 2024 | 533 | 0.790 |
Why?
|
| Logistic Models | 26 | 2024 | 13266 | 0.790 |
Why?
|
| Biomedical Research | 5 | 2023 | 3458 | 0.790 |
Why?
|
| Anger | 5 | 2008 | 402 | 0.780 |
Why?
|
| Massachusetts | 15 | 2024 | 8875 | 0.750 |
Why?
|
| Coronavirus Infections | 5 | 2022 | 3100 | 0.740 |
Why?
|
| Medical Informatics | 2 | 2018 | 745 | 0.740 |
Why?
|
| DNA Copy Number Variations | 7 | 2022 | 2045 | 0.740 |
Why?
|
| Periodicals as Topic | 4 | 2022 | 1462 | 0.740 |
Why?
|
| Drug Prescriptions | 4 | 2022 | 1662 | 0.740 |
Why?
|
| Pneumonia, Viral | 5 | 2022 | 3223 | 0.730 |
Why?
|
| Treatment Outcome | 67 | 2024 | 65188 | 0.730 |
Why?
|
| Patient Discharge | 4 | 2018 | 3461 | 0.730 |
Why?
|
| Calcium Channel Blockers | 3 | 2015 | 686 | 0.720 |
Why?
|
| ROC Curve | 13 | 2024 | 3620 | 0.720 |
Why?
|
| Adolescent | 60 | 2025 | 88835 | 0.710 |
Why?
|
| Synapses | 4 | 2020 | 1754 | 0.710 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 2780 | 0.700 |
Why?
|
| Decision Support Techniques | 6 | 2014 | 2003 | 0.700 |
Why?
|
| Conflict of Interest | 4 | 2018 | 556 | 0.690 |
Why?
|
| Postpartum Hemorrhage | 2 | 2021 | 276 | 0.690 |
Why?
|
| Affect | 10 | 2015 | 1500 | 0.680 |
Why?
|
| Social Isolation | 1 | 2023 | 366 | 0.670 |
Why?
|
| Multifactorial Inheritance | 9 | 2021 | 1425 | 0.670 |
Why?
|
| Length of Stay | 8 | 2024 | 6485 | 0.660 |
Why?
|
| Nitroprusside | 1 | 2019 | 271 | 0.630 |
Why?
|
| Phenotype | 30 | 2024 | 16721 | 0.630 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2019 | 65 | 0.620 |
Why?
|
| Reward | 8 | 2019 | 981 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2012 | 10383 | 0.610 |
Why?
|
| Aged | 60 | 2025 | 171117 | 0.600 |
Why?
|
| Arousal | 2 | 2018 | 1171 | 0.590 |
Why?
|
| Rett Syndrome | 1 | 2019 | 163 | 0.580 |
Why?
|
| Neuronal Plasticity | 4 | 2022 | 1445 | 0.580 |
Why?
|
| Isradipine | 2 | 2015 | 12 | 0.580 |
Why?
|
| Models, Statistical | 9 | 2021 | 5089 | 0.580 |
Why?
|
| Accidental Falls | 2 | 2017 | 1078 | 0.570 |
Why?
|
| Risk Assessment | 16 | 2024 | 24282 | 0.570 |
Why?
|
| New England | 6 | 2018 | 1059 | 0.570 |
Why?
|
| Psychotherapy | 4 | 2018 | 1645 | 0.570 |
Why?
|
| Coronavirus | 1 | 2020 | 155 | 0.570 |
Why?
|
| Young Adult | 40 | 2025 | 59889 | 0.570 |
Why?
|
| Drug Therapy, Combination | 18 | 2019 | 6309 | 0.570 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2018 | 146 | 0.570 |
Why?
|
| Costs and Cost Analysis | 3 | 2018 | 1668 | 0.560 |
Why?
|
| Double-Blind Method | 19 | 2020 | 12437 | 0.560 |
Why?
|
| Publications | 1 | 2019 | 195 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2025 | 2187 | 0.560 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2024 | 2531 | 0.550 |
Why?
|
| Behavioral Symptoms | 1 | 2019 | 187 | 0.550 |
Why?
|
| Wounds, Gunshot | 1 | 2023 | 585 | 0.550 |
Why?
|
| Prevalence | 17 | 2024 | 15842 | 0.550 |
Why?
|
| Retrospective Studies | 43 | 2024 | 81514 | 0.550 |
Why?
|
| Intensive Care Units | 3 | 2021 | 3800 | 0.540 |
Why?
|
| Genetic Association Studies | 6 | 2017 | 2741 | 0.540 |
Why?
|
| Hospital Mortality | 2 | 2021 | 5343 | 0.540 |
Why?
|
| Prefrontal Cortex | 7 | 2023 | 2224 | 0.530 |
Why?
|
| Documentation | 2 | 2020 | 916 | 0.530 |
Why?
|
| Drug Repositioning | 2 | 2018 | 246 | 0.530 |
Why?
|
| Drug Interactions | 3 | 2017 | 1417 | 0.530 |
Why?
|
| Hospital Departments | 1 | 2017 | 135 | 0.530 |
Why?
|
| Autistic Disorder | 2 | 2016 | 1239 | 0.530 |
Why?
|
| Desipramine | 2 | 2015 | 183 | 0.530 |
Why?
|
| Computer Security | 1 | 2018 | 261 | 0.520 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 325 | 0.520 |
Why?
|
| Delivery of Health Care | 4 | 2018 | 5370 | 0.510 |
Why?
|
| Anti-Anxiety Agents | 2 | 2018 | 402 | 0.510 |
Why?
|
| Spasms, Infantile | 1 | 2019 | 302 | 0.510 |
Why?
|
| Comorbidity | 27 | 2024 | 10563 | 0.510 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2018 | 1333 | 0.500 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2015 | 29 | 0.500 |
Why?
|
| Huntington Disease | 2 | 2015 | 1147 | 0.500 |
Why?
|
| Nerve Tissue Proteins | 10 | 2017 | 4392 | 0.500 |
Why?
|
| Accidents | 1 | 2016 | 164 | 0.490 |
Why?
|
| Firearms | 1 | 2023 | 630 | 0.490 |
Why?
|
| Drug Industry | 2 | 2016 | 791 | 0.490 |
Why?
|
| Case-Control Studies | 29 | 2024 | 22223 | 0.490 |
Why?
|
| Biological Specimen Banks | 2 | 2019 | 786 | 0.480 |
Why?
|
| Nootropic Agents | 2 | 2015 | 159 | 0.480 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15880 | 0.480 |
Why?
|
| Pregnancy Complications | 6 | 2024 | 2975 | 0.470 |
Why?
|
| Pregnancy | 27 | 2025 | 30260 | 0.470 |
Why?
|
| Early Diagnosis | 1 | 2020 | 1187 | 0.470 |
Why?
|
| Financial Support | 2 | 2005 | 116 | 0.470 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 2 | 2012 | 88 | 0.470 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2014 | 426 | 0.460 |
Why?
|
| Workload | 1 | 2020 | 851 | 0.460 |
Why?
|
| Longitudinal Studies | 24 | 2024 | 14751 | 0.460 |
Why?
|
| Central Nervous System Agents | 1 | 2015 | 72 | 0.460 |
Why?
|
| Drug Therapy | 2 | 2008 | 504 | 0.460 |
Why?
|
| Long QT Syndrome | 2 | 2017 | 474 | 0.460 |
Why?
|
| Patient Admission | 3 | 2021 | 1365 | 0.450 |
Why?
|
| Cocaine-Related Disorders | 2 | 2015 | 459 | 0.450 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2009 | 193 | 0.450 |
Why?
|
| Hospitals | 4 | 2024 | 3888 | 0.450 |
Why?
|
| Death | 1 | 2019 | 686 | 0.450 |
Why?
|
| Confidentiality | 1 | 2018 | 607 | 0.450 |
Why?
|
| Risk Factors | 47 | 2023 | 74840 | 0.450 |
Why?
|
| Mexican Americans | 1 | 2015 | 165 | 0.450 |
Why?
|
| United States | 26 | 2025 | 72903 | 0.450 |
Why?
|
| Drug Resistance | 6 | 2012 | 1591 | 0.440 |
Why?
|
| Trinucleotide Repeats | 1 | 2015 | 258 | 0.440 |
Why?
|
| Central Nervous System | 2 | 2019 | 1341 | 0.440 |
Why?
|
| Neurons | 11 | 2023 | 9525 | 0.430 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2015 | 605 | 0.420 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 8041 | 0.420 |
Why?
|
| Vaccination | 2 | 2025 | 3426 | 0.420 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2015 | 497 | 0.420 |
Why?
|
| Risk-Taking | 1 | 2019 | 1021 | 0.420 |
Why?
|
| National Institute of Mental Health (U.S.) | 4 | 2024 | 107 | 0.420 |
Why?
|
| Interleukins | 1 | 2018 | 791 | 0.420 |
Why?
|
| Methadone | 1 | 2015 | 319 | 0.410 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2012 | 57 | 0.400 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 79 | 0.400 |
Why?
|
| Benzothiazoles | 1 | 2013 | 246 | 0.390 |
Why?
|
| Patient Participation | 2 | 2019 | 1455 | 0.390 |
Why?
|
| Schizophrenic Psychology | 3 | 2017 | 1648 | 0.390 |
Why?
|
| Depression, Postpartum | 1 | 2017 | 360 | 0.390 |
Why?
|
| Remission Induction | 5 | 2020 | 2411 | 0.390 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2012 | 66 | 0.390 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 1652 | 0.380 |
Why?
|
| Carrier Proteins | 4 | 2018 | 4913 | 0.380 |
Why?
|
| Anxiety | 6 | 2024 | 4671 | 0.380 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 746 | 0.380 |
Why?
|
| Genetic Variation | 9 | 2018 | 6610 | 0.370 |
Why?
|
| Psychoses, Substance-Induced | 2 | 2024 | 98 | 0.370 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 2 | 2010 | 56 | 0.370 |
Why?
|
| Valproic Acid | 2 | 2011 | 445 | 0.370 |
Why?
|
| Medicare Part D | 1 | 2016 | 355 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2012 | 386 | 0.370 |
Why?
|
| Mitochondria | 3 | 2020 | 3673 | 0.370 |
Why?
|
| Avoidance Learning | 3 | 2010 | 248 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 1857 | 0.360 |
Why?
|
| Communication | 2 | 2023 | 3916 | 0.360 |
Why?
|
| Patient Compliance | 3 | 2019 | 2692 | 0.360 |
Why?
|
| Receptors, AMPA | 2 | 2009 | 334 | 0.350 |
Why?
|
| Personality Inventory | 8 | 2012 | 1018 | 0.350 |
Why?
|
| Disease Progression | 4 | 2020 | 13632 | 0.350 |
Why?
|
| Brain | 23 | 2024 | 27171 | 0.340 |
Why?
|
| Weight Gain | 5 | 2023 | 2355 | 0.340 |
Why?
|
| Drug Costs | 3 | 2016 | 1193 | 0.340 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 2966 | 0.340 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2709 | 0.330 |
Why?
|
| Journal Impact Factor | 2 | 2022 | 157 | 0.330 |
Why?
|
| Cognition | 9 | 2023 | 7049 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 8 | 2018 | 7425 | 0.330 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 804 | 0.330 |
Why?
|
| Intention | 1 | 2012 | 346 | 0.330 |
Why?
|
| Forecasting | 1 | 2018 | 2936 | 0.320 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 722 | 0.320 |
Why?
|
| Models, Biological | 3 | 2021 | 9443 | 0.320 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 9525 | 0.320 |
Why?
|
| Thinking | 1 | 2012 | 322 | 0.320 |
Why?
|
| Organoids | 4 | 2023 | 739 | 0.320 |
Why?
|
| Social Environment | 1 | 2014 | 1011 | 0.320 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 59489 | 0.310 |
Why?
|
| Neuroglia | 1 | 2014 | 964 | 0.310 |
Why?
|
| Computational Biology | 1 | 2020 | 3559 | 0.310 |
Why?
|
| Pattern Recognition, Visual | 3 | 2010 | 820 | 0.300 |
Why?
|
| Alleles | 10 | 2016 | 6897 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1892 | 0.300 |
Why?
|
| Area Under Curve | 4 | 2021 | 1638 | 0.300 |
Why?
|
| Probability Learning | 1 | 2008 | 23 | 0.300 |
Why?
|
| Sex Factors | 9 | 2022 | 10603 | 0.290 |
Why?
|
| Facial Expression | 2 | 2009 | 516 | 0.290 |
Why?
|
| Decision Making | 3 | 2018 | 3965 | 0.290 |
Why?
|
| Inpatients | 1 | 2019 | 2564 | 0.290 |
Why?
|
| Mental Health Services | 2 | 2024 | 1723 | 0.290 |
Why?
|
| Triazines | 1 | 2009 | 307 | 0.290 |
Why?
|
| Risperidone | 2 | 2007 | 383 | 0.290 |
Why?
|
| Prescriptions | 2 | 2021 | 388 | 0.290 |
Why?
|
| Critical Illness | 1 | 2020 | 2744 | 0.280 |
Why?
|
| Recurrence | 10 | 2014 | 8501 | 0.280 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 363 | 0.280 |
Why?
|
| International Classification of Diseases | 3 | 2020 | 935 | 0.280 |
Why?
|
| Stress, Psychological | 5 | 2014 | 4533 | 0.280 |
Why?
|
| Odds Ratio | 7 | 2022 | 9649 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 4058 | 0.270 |
Why?
|
| Social Behavior | 2 | 2016 | 1146 | 0.270 |
Why?
|
| Labor Stage, Second | 2 | 2024 | 45 | 0.270 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 2128 | 0.270 |
Why?
|
| Electroconvulsive Therapy | 3 | 2024 | 506 | 0.270 |
Why?
|
| Health Care Costs | 5 | 2019 | 3242 | 0.270 |
Why?
|
| Behavior Therapy | 1 | 2012 | 884 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2024 | 10729 | 0.260 |
Why?
|
| Bupropion | 4 | 2014 | 303 | 0.260 |
Why?
|
| Databases, Factual | 5 | 2019 | 8067 | 0.260 |
Why?
|
| Biotransformation | 1 | 2006 | 165 | 0.260 |
Why?
|
| Placenta | 3 | 2024 | 1728 | 0.260 |
Why?
|
| Child | 20 | 2024 | 80564 | 0.260 |
Why?
|
| Apgar Score | 2 | 2024 | 124 | 0.250 |
Why?
|
| Cause of Death | 1 | 2016 | 3708 | 0.250 |
Why?
|
| Linkage Disequilibrium | 8 | 2012 | 1997 | 0.250 |
Why?
|
| Critical Care | 1 | 2018 | 2712 | 0.250 |
Why?
|
| Emotions | 2 | 2015 | 2763 | 0.250 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 4247 | 0.250 |
Why?
|
| Physicians | 3 | 2024 | 4588 | 0.250 |
Why?
|
| Telecommunications | 2 | 2020 | 79 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2013 | 2247 | 0.240 |
Why?
|
| Models, Neurological | 1 | 2013 | 1747 | 0.240 |
Why?
|
| Child Abuse | 1 | 2014 | 1090 | 0.240 |
Why?
|
| Dementia | 1 | 2020 | 2744 | 0.240 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 26318 | 0.240 |
Why?
|
| Population Groups | 1 | 2006 | 209 | 0.240 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 7875 | 0.230 |
Why?
|
| Nortriptyline | 3 | 2014 | 78 | 0.230 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 12976 | 0.230 |
Why?
|
| Language | 2 | 2024 | 1550 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2012 | 5526 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2008 | 952 | 0.230 |
Why?
|
| Dermatology | 3 | 2018 | 907 | 0.230 |
Why?
|
| Diagnostic Errors | 2 | 2016 | 1275 | 0.230 |
Why?
|
| Infant, Newborn | 11 | 2024 | 26346 | 0.220 |
Why?
|
| Delivery, Obstetric | 5 | 2024 | 946 | 0.220 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 3819 | 0.220 |
Why?
|
| Mortality | 1 | 2015 | 2904 | 0.220 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2011 | 1090 | 0.220 |
Why?
|
| Ivermectin | 1 | 2023 | 48 | 0.210 |
Why?
|
| Prospective Studies | 21 | 2023 | 54802 | 0.210 |
Why?
|
| Algorithms | 10 | 2021 | 14071 | 0.210 |
Why?
|
| Electrocardiography | 2 | 2015 | 6404 | 0.210 |
Why?
|
| Child, Preschool | 10 | 2023 | 42500 | 0.210 |
Why?
|
| Research Design | 5 | 2019 | 6209 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2268 | 0.200 |
Why?
|
| Age of Onset | 7 | 2010 | 3344 | 0.200 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2021 | 605 | 0.200 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 3475 | 0.200 |
Why?
|
| Serotonin | 1 | 2007 | 1049 | 0.200 |
Why?
|
| Membrane Glycoproteins | 4 | 2012 | 3690 | 0.190 |
Why?
|
| Health Surveys | 1 | 2012 | 4056 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 2511 | 0.190 |
Why?
|
| Labor, Obstetric | 2 | 2021 | 317 | 0.190 |
Why?
|
| Reversal Learning | 1 | 2022 | 55 | 0.190 |
Why?
|
| Age Factors | 6 | 2021 | 18380 | 0.190 |
Why?
|
| Cytokines | 4 | 2025 | 7421 | 0.180 |
Why?
|
| Fetal Blood | 3 | 2025 | 1369 | 0.180 |
Why?
|
| Genome | 1 | 2009 | 1753 | 0.180 |
Why?
|
| Risk | 4 | 2019 | 9591 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Hydro-Lyases | 1 | 2020 | 93 | 0.180 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 189 | 0.170 |
Why?
|
| Loneliness | 1 | 2023 | 211 | 0.170 |
Why?
|
| Time Factors | 11 | 2020 | 40065 | 0.170 |
Why?
|
| Neuropsychological Tests | 5 | 2021 | 7123 | 0.170 |
Why?
|
| Clozapine | 2 | 2019 | 509 | 0.170 |
Why?
|
| Medicine | 2 | 2021 | 942 | 0.170 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 158 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 3278 | 0.170 |
Why?
|
| Cholinergic Antagonists | 1 | 2021 | 165 | 0.170 |
Why?
|
| Secondary Prevention | 6 | 2010 | 1472 | 0.170 |
Why?
|
| Labor, Induced | 1 | 2021 | 153 | 0.170 |
Why?
|
| Resilience, Psychological | 2 | 2021 | 806 | 0.170 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 14652 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2018 | 624 | 0.170 |
Why?
|
| Chromosome Disorders | 1 | 2022 | 498 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2023 | 341 | 0.160 |
Why?
|
| Tryptophan Hydroxylase | 2 | 2012 | 93 | 0.160 |
Why?
|
| Methylphenidate | 2 | 2024 | 479 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 431 | 0.160 |
Why?
|
| Ownership | 1 | 2022 | 338 | 0.160 |
Why?
|
| Astrocytes | 3 | 2022 | 1345 | 0.160 |
Why?
|
| Kynurenic Acid | 1 | 2019 | 44 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 3835 | 0.160 |
Why?
|
| Cerebrum | 1 | 2020 | 131 | 0.160 |
Why?
|
| Motivation | 2 | 2010 | 2018 | 0.160 |
Why?
|
| Membrane Transport Proteins | 2 | 2005 | 1028 | 0.160 |
Why?
|
| Anticonvulsants | 3 | 2020 | 1921 | 0.160 |
Why?
|
| Drug Administration Schedule | 7 | 2007 | 4850 | 0.150 |
Why?
|
| Calcium Signaling | 1 | 2023 | 733 | 0.150 |
Why?
|
| Electrophysiological Phenomena | 1 | 2020 | 307 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 790 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 39193 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 5783 | 0.150 |
Why?
|
| Ambulatory Care | 6 | 2011 | 2778 | 0.150 |
Why?
|
| Akathisia, Drug-Induced | 2 | 2009 | 63 | 0.150 |
Why?
|
| Incidence | 8 | 2021 | 21480 | 0.150 |
Why?
|
| Amphetamine | 1 | 2019 | 222 | 0.150 |
Why?
|
| Gene Expression Regulation | 5 | 2022 | 11888 | 0.140 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2009 | 326 | 0.140 |
Why?
|
| Histone Deacetylases | 2 | 2020 | 708 | 0.140 |
Why?
|
| Platelet Count | 1 | 2020 | 782 | 0.140 |
Why?
|
| Minocycline | 1 | 2019 | 168 | 0.140 |
Why?
|
| Health Status | 3 | 2008 | 4080 | 0.140 |
Why?
|
| Mandatory Reporting | 1 | 2018 | 123 | 0.140 |
Why?
|
| Prognosis | 8 | 2021 | 29922 | 0.140 |
Why?
|
| Health Personnel | 3 | 2021 | 3390 | 0.140 |
Why?
|
| Headache | 2 | 2021 | 1259 | 0.140 |
Why?
|
| Cerebral Cortex | 3 | 2022 | 5767 | 0.140 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 20124 | 0.140 |
Why?
|
| Ankyrins | 3 | 2017 | 123 | 0.140 |
Why?
|
| Mifepristone | 1 | 2018 | 150 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6499 | 0.140 |
Why?
|
| Consumer Health Information | 1 | 2019 | 215 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2019 | 10070 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 6069 | 0.140 |
Why?
|
| Insurance Claim Reporting | 1 | 2017 | 166 | 0.130 |
Why?
|
| Ethical Theory | 1 | 2016 | 34 | 0.130 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2018 | 361 | 0.130 |
Why?
|
| Cost of Illness | 4 | 2019 | 1950 | 0.130 |
Why?
|
| Calcium | 3 | 2023 | 5767 | 0.130 |
Why?
|
| Complement C4 | 1 | 2016 | 208 | 0.130 |
Why?
|
| Nerve Net | 1 | 2008 | 2309 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 71 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2019 | 18973 | 0.130 |
Why?
|
| Docosahexaenoic Acids | 2 | 2020 | 916 | 0.130 |
Why?
|
| Phosphocreatine | 1 | 2016 | 258 | 0.130 |
Why?
|
| Markov Chains | 2 | 2012 | 968 | 0.130 |
Why?
|
| Hydrocarbons, Iodinated | 1 | 2015 | 8 | 0.130 |
Why?
|
| Physicians, Women | 1 | 2022 | 512 | 0.120 |
Why?
|
| Eosinophils | 1 | 2020 | 945 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2021 | 635 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2013 | 4300 | 0.120 |
Why?
|
| Haplotypes | 5 | 2008 | 2728 | 0.120 |
Why?
|
| Europe | 3 | 2017 | 3423 | 0.120 |
Why?
|
| Current Procedural Terminology | 1 | 2016 | 100 | 0.120 |
Why?
|
| Troponin T | 1 | 2020 | 785 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
| Oxazoles | 1 | 2016 | 198 | 0.120 |
Why?
|
| Fatigue | 1 | 2022 | 1549 | 0.120 |
Why?
|
| Electronic Prescribing | 1 | 2016 | 115 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 2 | 2016 | 1087 | 0.120 |
Why?
|
| Buspirone | 2 | 2012 | 80 | 0.120 |
Why?
|
| Cyclohexanols | 2 | 2012 | 127 | 0.120 |
Why?
|
| Creatinine | 1 | 2020 | 1915 | 0.120 |
Why?
|
| Publication Bias | 2 | 2005 | 158 | 0.120 |
Why?
|
| Membrane Potentials | 2 | 2015 | 1083 | 0.120 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2014 | 30 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 1175 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2012 | 2077 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2229 | 0.110 |
Why?
|
| Positron-Emission Tomography | 4 | 2020 | 6547 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 1731 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2017 | 3564 | 0.110 |
Why?
|
| Neuroma, Acoustic | 1 | 2018 | 456 | 0.110 |
Why?
|
| Judgment | 1 | 2016 | 270 | 0.110 |
Why?
|
| Amitriptyline | 1 | 2014 | 109 | 0.110 |
Why?
|
| Violence | 1 | 2020 | 935 | 0.110 |
Why?
|
| Cadherins | 1 | 2019 | 900 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 1167 | 0.110 |
Why?
|
| Anorexia Nervosa | 1 | 2023 | 1328 | 0.110 |
Why?
|
| Interneurons | 1 | 2019 | 593 | 0.110 |
Why?
|
| Fructose | 1 | 2016 | 286 | 0.110 |
Why?
|
| Texas | 2 | 2005 | 410 | 0.110 |
Why?
|
| Outpatients | 3 | 2019 | 1595 | 0.110 |
Why?
|
| Insurance | 1 | 2015 | 115 | 0.110 |
Why?
|
| Sertraline | 2 | 2012 | 209 | 0.110 |
Why?
|
| Combined Modality Therapy | 5 | 2012 | 8529 | 0.110 |
Why?
|
| Isotope Labeling | 1 | 2015 | 389 | 0.110 |
Why?
|
| Perinatal Care | 1 | 2016 | 246 | 0.110 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2659 | 0.110 |
Why?
|
| Morals | 1 | 2016 | 288 | 0.110 |
Why?
|
| Alcohol-Related Disorders | 1 | 2016 | 242 | 0.110 |
Why?
|
| Oxygen | 2 | 2019 | 4241 | 0.110 |
Why?
|
| Dopamine Agonists | 2 | 2013 | 346 | 0.110 |
Why?
|
| Heart Failure | 1 | 2017 | 11840 | 0.100 |
Why?
|
| Placebos | 3 | 2006 | 1659 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2016 | 6322 | 0.100 |
Why?
|
| Penetrance | 1 | 2015 | 388 | 0.100 |
Why?
|
| Medical Records | 1 | 2018 | 1409 | 0.100 |
Why?
|
| England | 1 | 2014 | 533 | 0.100 |
Why?
|
| Infant | 5 | 2024 | 36386 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 2900 | 0.100 |
Why?
|
| Tablets | 1 | 2013 | 149 | 0.100 |
Why?
|
| Phosphates | 1 | 2016 | 763 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 8923 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2023 | 2968 | 0.100 |
Why?
|
| Propensity Score | 2 | 2018 | 1968 | 0.100 |
Why?
|
| Health Behavior | 1 | 2024 | 2650 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 2 | 2016 | 1370 | 0.100 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2014 | 597 | 0.100 |
Why?
|
| Drug Substitution | 2 | 2012 | 292 | 0.100 |
Why?
|
| Demography | 4 | 2006 | 1641 | 0.100 |
Why?
|
| Cell Line | 3 | 2022 | 15543 | 0.100 |
Why?
|
| Receptor, Melanocortin, Type 3 | 1 | 2012 | 12 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 452 | 0.100 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2009 | 74 | 0.100 |
Why?
|
| Executive Function | 2 | 2024 | 1391 | 0.100 |
Why?
|
| Macrophages | 2 | 2024 | 5772 | 0.100 |
Why?
|
| Wireless Technology | 1 | 2013 | 99 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2020 | 1142 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2009 | 61 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2021 | 2643 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2017 | 2243 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2013 | 8733 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12056 | 0.100 |
Why?
|
| Ketamine | 1 | 2018 | 525 | 0.100 |
Why?
|
| Disease | 1 | 2017 | 676 | 0.100 |
Why?
|
| Genome, Human | 4 | 2021 | 4448 | 0.100 |
Why?
|
| Telemetry | 1 | 2013 | 201 | 0.100 |
Why?
|
| Crohn Disease | 3 | 2013 | 2283 | 0.100 |
Why?
|
| Psychomotor Performance | 3 | 2011 | 1881 | 0.100 |
Why?
|
| Acute Disease | 1 | 2022 | 7232 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2013 | 1749 | 0.090 |
Why?
|
| Reinforcement Schedule | 2 | 2010 | 123 | 0.090 |
Why?
|
| Registries | 3 | 2019 | 8297 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2015 | 453 | 0.090 |
Why?
|
| Patient Selection | 3 | 2020 | 4255 | 0.090 |
Why?
|
| Mothers | 1 | 2022 | 2210 | 0.090 |
Why?
|
| Learning | 2 | 2011 | 1755 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 3672 | 0.090 |
Why?
|
| Quality of Life | 6 | 2009 | 13462 | 0.090 |
Why?
|
| Gene Frequency | 5 | 2010 | 3624 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 7838 | 0.090 |
Why?
|
| Monocytes | 1 | 2020 | 2595 | 0.090 |
Why?
|
| Disease Susceptibility | 2 | 2023 | 1789 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4642 | 0.090 |
Why?
|
| Triazoles | 1 | 2016 | 897 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2015 | 824 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2023 | 11641 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 1396 | 0.090 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 1915 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2020 | 3449 | 0.090 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 499 | 0.090 |
Why?
|
| Synaptosomal-Associated Protein 25 | 2 | 2007 | 50 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3141 | 0.090 |
Why?
|
| Substance-Related Disorders | 5 | 2018 | 4416 | 0.090 |
Why?
|
| Receptor, Melanocortin, Type 2 | 1 | 2009 | 9 | 0.090 |
Why?
|
| Receptors, Histamine H1 | 1 | 2009 | 20 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 728 | 0.090 |
Why?
|
| GABA Modulators | 1 | 2010 | 108 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2021 | 3595 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2218 | 0.080 |
Why?
|
| Guideline Adherence | 3 | 2010 | 2243 | 0.080 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2010 | 74 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2017 | 1205 | 0.080 |
Why?
|
| Animals | 13 | 2024 | 168764 | 0.080 |
Why?
|
| Psychomotor Agitation | 2 | 2020 | 304 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 36532 | 0.080 |
Why?
|
| Primary Health Care | 2 | 2019 | 4736 | 0.080 |
Why?
|
| Limbic System | 1 | 2012 | 418 | 0.080 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2009 | 471 | 0.080 |
Why?
|
| Bronchiolitis | 1 | 2016 | 493 | 0.080 |
Why?
|
| Ventral Tegmental Area | 1 | 2010 | 136 | 0.080 |
Why?
|
| Causality | 1 | 2016 | 1248 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2019 | 2521 | 0.080 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 834 | 0.080 |
Why?
|
| Lorazepam | 1 | 2010 | 155 | 0.080 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2009 | 106 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 412 | 0.080 |
Why?
|
| Attention | 4 | 2024 | 2419 | 0.080 |
Why?
|
| Cyclothymic Disorder | 1 | 2009 | 44 | 0.080 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2010 | 167 | 0.080 |
Why?
|
| Alcoholism | 2 | 2010 | 1975 | 0.080 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 2 | 2005 | 36 | 0.080 |
Why?
|
| Basal Ganglia Diseases | 1 | 2009 | 145 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 457 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2010 | 346 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2022 | 2652 | 0.080 |
Why?
|
| North America | 1 | 2012 | 1285 | 0.080 |
Why?
|
| Parity | 2 | 2023 | 931 | 0.080 |
Why?
|
| Calibration | 1 | 2011 | 814 | 0.080 |
Why?
|
| Glucose | 1 | 2020 | 4335 | 0.080 |
Why?
|
| Empathy | 1 | 2013 | 474 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3850 | 0.080 |
Why?
|
| Internet | 2 | 2019 | 3106 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2019 | 2892 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2352 | 0.080 |
Why?
|
| Dermatitis, Atopic | 1 | 2016 | 729 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 591 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 632 | 0.080 |
Why?
|
| Boston | 2 | 2018 | 9338 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2017 | 1325 | 0.080 |
Why?
|
| Benzophenones | 1 | 2008 | 58 | 0.070 |
Why?
|
| Body Mass Index | 5 | 2024 | 13039 | 0.070 |
Why?
|
| Reference Standards | 1 | 2012 | 1013 | 0.070 |
Why?
|
| Myosin Type V | 1 | 2008 | 31 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2009 | 378 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2010 | 780 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2008 | 169 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12509 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3776 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2009 | 308 | 0.070 |
Why?
|
| Sialyltransferases | 1 | 2008 | 83 | 0.070 |
Why?
|
| Episode of Care | 2 | 2005 | 128 | 0.070 |
Why?
|
| Hostility | 1 | 2008 | 185 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 101 | 0.070 |
Why?
|
| Premature Birth | 2 | 2017 | 1829 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2013 | 962 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2012 | 1158 | 0.070 |
Why?
|
| Personality | 1 | 2010 | 560 | 0.070 |
Why?
|
| Dominance, Cerebral | 1 | 2008 | 616 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2012 | 1180 | 0.070 |
Why?
|
| Gene Expression | 3 | 2015 | 7584 | 0.070 |
Why?
|
| Hyperprolactinemia | 1 | 2007 | 122 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2007 | 108 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2233 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 3685 | 0.070 |
Why?
|
| Rodentia | 1 | 2008 | 261 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 1175 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3956 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 402 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 641 | 0.060 |
Why?
|
| Association Learning | 1 | 2008 | 219 | 0.060 |
Why?
|
| Discrimination Learning | 1 | 2008 | 276 | 0.060 |
Why?
|
| Fetus | 2 | 2024 | 1870 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2006 | 368 | 0.060 |
Why?
|
| Medicaid | 1 | 2019 | 2833 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2011 | 456 | 0.060 |
Why?
|
| tau Proteins | 1 | 2016 | 2112 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2016 | 2589 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1792 | 0.060 |
Why?
|
| Mental Health | 1 | 2020 | 3278 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 698 | 0.060 |
Why?
|
| Linear Models | 1 | 2015 | 5876 | 0.060 |
Why?
|
| Neurogenesis | 2 | 2023 | 866 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2699 | 0.060 |
Why?
|
| Frontal Lobe | 2 | 2009 | 1410 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 15398 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 103 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2010 | 1140 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 218 | 0.060 |
Why?
|
| Appetite | 1 | 2006 | 247 | 0.060 |
Why?
|
| Cardiotocography | 1 | 2024 | 33 | 0.060 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 687 | 0.060 |
Why?
|
| Leptin | 1 | 2012 | 1596 | 0.060 |
Why?
|
| Gestational Age | 2 | 2024 | 3609 | 0.060 |
Why?
|
| Educational Status | 1 | 2012 | 2513 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 663 | 0.060 |
Why?
|
| Psychometrics | 5 | 2016 | 3062 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2023 | 3785 | 0.060 |
Why?
|
| Quinolones | 1 | 2007 | 387 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3797 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2015 | 1484 | 0.060 |
Why?
|
| Self Concept | 1 | 2010 | 1037 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2017 | 469 | 0.060 |
Why?
|
| Amphetamines | 1 | 2024 | 143 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2005 | 231 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2016 | 414 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2024 | 113 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2005 | 496 | 0.050 |
Why?
|
| Dizziness | 1 | 2006 | 269 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2015 | 12768 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2844 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2006 | 219 | 0.050 |
Why?
|
| Pedigree | 2 | 2008 | 4526 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2008 | 951 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3413 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2007 | 2424 | 0.050 |
Why?
|
| Sleep Stages | 1 | 2006 | 698 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2017 | 274 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2006 | 303 | 0.050 |
Why?
|
| RNA | 2 | 2022 | 2717 | 0.050 |
Why?
|
| Evoked Potentials | 2 | 2011 | 1048 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1737 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2007 | 500 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 4520 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2008 | 844 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2024 | 240 | 0.050 |
Why?
|
| Time | 1 | 2004 | 550 | 0.050 |
Why?
|
| Androgens | 1 | 2009 | 1279 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2415 | 0.050 |
Why?
|
| Orgasm | 1 | 2002 | 63 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7478 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2003 | 222 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 1003 | 0.050 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 185 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5508 | 0.050 |
Why?
|
| Mental Recall | 1 | 2008 | 1218 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 2410 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 300 | 0.050 |
Why?
|
| Sulfurtransferases | 1 | 2021 | 17 | 0.050 |
Why?
|
| Libido | 1 | 2002 | 123 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2012 | 6255 | 0.050 |
Why?
|
| Calcium Channels | 2 | 2015 | 622 | 0.050 |
Why?
|
| Ghrelin | 1 | 2023 | 255 | 0.050 |
Why?
|
| Medicare | 1 | 2019 | 6823 | 0.050 |
Why?
|
| Mass Screening | 1 | 2017 | 5446 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2022 | 340 | 0.040 |
Why?
|
| Interview, Psychological | 1 | 2004 | 812 | 0.040 |
Why?
|
| Malpractice | 1 | 2006 | 561 | 0.040 |
Why?
|
| Drug Design | 1 | 2006 | 1042 | 0.040 |
Why?
|
| Calcinosis | 1 | 2009 | 1479 | 0.040 |
Why?
|
| Presynaptic Terminals | 1 | 2022 | 297 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2007 | 869 | 0.040 |
Why?
|
| Thiazoles | 1 | 2007 | 1529 | 0.040 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2007 | 1484 | 0.040 |
Why?
|
| Electroencephalography | 2 | 2008 | 6273 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 2686 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 2002 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5696 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2005 | 1009 | 0.040 |
Why?
|
| Chromosome Mapping | 4 | 2010 | 4618 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4108 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1672 | 0.040 |
Why?
|
| Mice | 6 | 2024 | 81819 | 0.040 |
Why?
|
| Homozygote | 2 | 2016 | 1775 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 437 | 0.040 |
Why?
|
| Paroxetine | 1 | 2020 | 180 | 0.040 |
Why?
|
| Microelectrodes | 1 | 2020 | 304 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2006 | 2499 | 0.040 |
Why?
|
| Testosterone | 1 | 2009 | 2494 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5891 | 0.040 |
Why?
|
| Family | 2 | 2007 | 3209 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2020 | 358 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1509 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2005 | 1247 | 0.040 |
Why?
|
| Erectile Dysfunction | 1 | 2002 | 437 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2024 | 587 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2021 | 879 | 0.040 |
Why?
|
| Cardiovascular Diseases | 4 | 2009 | 15652 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2021 | 752 | 0.040 |
Why?
|
| Anisotropy | 2 | 2012 | 1282 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2011 | 993 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2022 | 1385 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 1657 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2012 | 7851 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 660 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3715 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2018 | 317 | 0.040 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 959 | 0.040 |
Why?
|
| Parturition | 1 | 2021 | 454 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2022 | 1599 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 565 | 0.030 |
Why?
|
| Hypertension | 2 | 2015 | 8626 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2016 | 67 | 0.030 |
Why?
|
| Piperazines | 1 | 2007 | 2549 | 0.030 |
Why?
|
| Telemedicine | 2 | 2024 | 3105 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2016 | 13 | 0.030 |
Why?
|
| Genetic Markers | 3 | 2008 | 2601 | 0.030 |
Why?
|
| Aminopeptidases | 1 | 2017 | 113 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2017 | 198 | 0.030 |
Why?
|
| Dimethylformamide | 1 | 2015 | 20 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 23601 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2017 | 237 | 0.030 |
Why?
|
| Smoking | 2 | 2009 | 9081 | 0.030 |
Why?
|
| Systems Biology | 1 | 2019 | 481 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 5077 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2010 | 412 | 0.030 |
Why?
|
| International Cooperation | 2 | 2013 | 1432 | 0.030 |
Why?
|
| Phosphorus | 1 | 2016 | 337 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 2453 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 1526 | 0.030 |
Why?
|
| Calcium Channel Agonists | 1 | 2014 | 26 | 0.030 |
Why?
|
| Genomics | 2 | 2022 | 5929 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2172 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 18293 | 0.030 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2015 | 120 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 1354 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2015 | 204 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 2878 | 0.030 |
Why?
|
| Indoles | 1 | 2002 | 1839 | 0.030 |
Why?
|
| Genetic Linkage | 2 | 2010 | 2341 | 0.030 |
Why?
|
| Transcription Factors | 4 | 2015 | 12131 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 644 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 543 | 0.030 |
Why?
|
| Editorial Policies | 1 | 2018 | 458 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 98 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2014 | 504 | 0.030 |
Why?
|
| Integrins | 1 | 2017 | 840 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 726 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 2140 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 570 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 1381 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 2034 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 22332 | 0.020 |
Why?
|
| Genes, Mitochondrial | 1 | 2012 | 59 | 0.020 |
Why?
|
| Lipids | 1 | 2023 | 3315 | 0.020 |
Why?
|
| Child Development | 1 | 2024 | 2327 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2012 | 70 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 4405 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2016 | 1885 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 1195 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2013 | 242 | 0.020 |
Why?
|
| Reference Values | 2 | 2010 | 4908 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 898 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 13076 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 1947 | 0.020 |
Why?
|
| Behavior | 1 | 2014 | 535 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2012 | 212 | 0.020 |
Why?
|
| Brain Mapping | 3 | 2011 | 6601 | 0.020 |
Why?
|
| Feedback, Psychological | 1 | 2011 | 97 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5302 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 345 | 0.020 |
Why?
|
| China | 1 | 2017 | 2385 | 0.020 |
Why?
|
| Medial Forebrain Bundle | 1 | 2010 | 42 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2014 | 1336 | 0.020 |
Why?
|
| Income | 1 | 2019 | 1874 | 0.020 |
Why?
|
| Adrenomedullin | 1 | 2010 | 85 | 0.020 |
Why?
|
| Bromocriptine | 1 | 2010 | 93 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15747 | 0.020 |
Why?
|
| Beauty | 1 | 2010 | 41 | 0.020 |
Why?
|
| Family Health | 1 | 2015 | 1253 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 502 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 735 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3540 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3432 | 0.020 |
Why?
|
| Receptors, Kainic Acid | 1 | 2009 | 91 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2013 | 893 | 0.020 |
Why?
|
| Diazepam | 1 | 2010 | 215 | 0.020 |
Why?
|
| Electrolytes | 1 | 2010 | 280 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2013 | 796 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2009 | 860 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4353 | 0.020 |
Why?
|
| Euphoria | 1 | 2009 | 64 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2017 | 1364 | 0.020 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2009 | 151 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 904 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2017 | 2354 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 999 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2010 | 646 | 0.020 |
Why?
|
| Haloperidol | 1 | 2010 | 391 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Glycolysis | 1 | 2012 | 838 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2009 | 287 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2016 | 8278 | 0.020 |
Why?
|
| Rats | 2 | 2015 | 23707 | 0.020 |
Why?
|
| Cognition Disorders | 2 | 2014 | 3967 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 715 | 0.020 |
Why?
|
| Catatonia | 1 | 2010 | 181 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3596 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 360 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 430 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 366 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2010 | 549 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2019 | 2387 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2010 | 584 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 952 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 2615 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5379 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 1117 | 0.020 |
Why?
|
| Food | 1 | 2010 | 764 | 0.020 |
Why?
|
| Receptors, Dopamine D5 | 1 | 2005 | 32 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6942 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2012 | 2927 | 0.010 |
Why?
|
| Adoption | 1 | 2005 | 97 | 0.010 |
Why?
|
| Pulse | 1 | 2004 | 215 | 0.010 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2005 | 168 | 0.010 |
Why?
|
| Liability, Legal | 1 | 2006 | 209 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2014 | 4159 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1993 | 2423 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2008 | 777 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 8102 | 0.010 |
Why?
|
| DNA | 2 | 2008 | 7202 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1405 | 0.010 |
Why?
|
| Tourette Syndrome | 1 | 2007 | 400 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2010 | 1993 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3202 | 0.010 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2005 | 276 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 12240 | 0.010 |
Why?
|
| Behavior, Addictive | 1 | 2008 | 423 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14448 | 0.010 |
Why?
|
| Motor Activity | 1 | 2013 | 2704 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2012 | 4137 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 4040 | 0.010 |
Why?
|
| Life Change Events | 1 | 2008 | 954 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2009 | 1187 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2739 | 0.010 |
Why?
|
| Fathers | 1 | 2005 | 376 | 0.010 |
Why?
|
| Movement | 1 | 2009 | 1462 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13648 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8611 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2006 | 514 | 0.010 |
Why?
|
| Heart Rate | 1 | 2013 | 4204 | 0.010 |
Why?
|
| Seizures | 1 | 2014 | 3000 | 0.010 |
Why?
|
| Amygdala | 1 | 2009 | 1377 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 17075 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 574 | 0.010 |
Why?
|
| Postmenopause | 1 | 2009 | 2515 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3561 | 0.010 |
Why?
|
| Women's Health | 1 | 2009 | 2084 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1441 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20659 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2003 | 610 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 1149 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2108 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 4772 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2007 | 1393 | 0.010 |
Why?
|
| Medical Errors | 1 | 2006 | 1260 | 0.010 |
Why?
|
| Sleep | 1 | 2013 | 4813 | 0.010 |
Why?
|
| Asthma | 1 | 2016 | 6270 | 0.010 |
Why?
|
| Hippocampus | 1 | 2009 | 3775 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 3318 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 12403 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2898 | 0.010 |
Why?
|
| Melanoma | 1 | 1993 | 5719 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2010 | 4862 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 1993 | 194 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 745 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 6424 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 30198 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 1993 | 723 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 8532 | 0.000 |
Why?
|
| Cell Division | 1 | 1993 | 4475 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 6113 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2003 | 4628 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13400 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 17594 | 0.000 |
Why?
|